Skip to main content
EJNMMI Research
Fig. 3 | EJNMMI Research

Fig. 3

From: Impact of rifampicin-inhibitable transport on the liver distribution and tissue kinetics of erlotinib assessed with PET imaging in rats

Fig. 3

Metabolism and plasma kinetics of 11C-erlotinib in the absence (control) and the presence of rifampicin (40 mg/kg i.v.). Data were obtained using arterial blood sampling (femoral artery) in additional rats (1 animal for each condition). In a, the percentage of parent (unmetabolized) 11C-erlotinib versus time is displayed. Corresponding plasma kinetics of parent 11C-erlotinib (metabolite-corrected arterial input function) are shown in b

Back to article page